3D Bioprinting Solutions

3D Bioprinting Solutions is a Laboratory for Biotechnological Research founded by INVITRO, the largest private medical company in Russia. The laboratory develops and produces bioprinters and materials for 3D bioprinting, and also develops innovative technologies in the field of biofabrication. 

An international multi-disciplinary team of researchers, world-class scientists, engineers and management was assembled for this new laboratory. Vladimir Mironov, one of the recognized pioneers of robotic biofabrication, Professor of the Department of Chemical and Life Science Engineering at Virginia Commonwealth University (USA), became the laboratory’s Head of Research.

Read More About 3DBio

FABION 2

FABION 2 is the next generation top-ranked bioprinter able to print complex structures using tissue spheroids and a wide range of hydrogels with different types of polymerization: thermosensitive hydrogels, multi-component hydrogels, photosensitive, Ph-sensitive and ionic-sensitive hydrogels.

ORGAN.AUT

Novel 3D bioprinter which enables rapid label-free 3D biofabrication of 3D tissue and organ constructs in the condition of microgravity using magnetic fields. Using microgravity as a co-factor of bioprinting technology allowed us to apply scaffold-free, nozzle-free, and label-free (without using magnetic nano-particles) approach so called “formative” biofabrication which has the edge over classical bottom-up additive manufacturing.

3D bioprinter «Organ.Aut» is a part of ISS scientific equipment which allows any scientific groups and companies interested in the 3D bioprinting technology to conduct international experiments.

 

VISCOLL

Viscoll is our new line of versatile collagen products suitable for any 3D bioprinter. It provides life science companies, researchers and innovators working in biofabrication with a powerful tool which offers unprecedented capabilities in experiments.

Contacts:
web:   www.bioprinting.ru
e-mail: info@bioprinting.ru

tel:       +7 (499) 769-50-18

CollPlant Ltd.

CollPlant (NASDAQ:CLGN) is a regenerative medicine company focused on developing and commercializing BioInks for 3D bioprinting and tissue repair products. CollPlant’s products are based on its recombinant human collagen (rhCollagen) which is produced in genetically engineered tobacco plants using CollPlant’s proprietary technology. The Company’s products, which address 3D bioprinting, medical aesthetics, orthopedics and advanced wound care, are ushering in a new era in regenerative medicine. Commercialization of CollPlant’s three lead products including BioInk, VergenixSTR for tendon repair, and VergenixFG for wound care, was initiated in 2017. They address multi-billion dollar markets worldwide.

Read More About CollPlant

Vision
We strive to be the leading company in the field of regenerative medicine by delivering innovative products that offer the best treatment options to patients and their physicians.

Technology
CollPlant’s technology is the only commercially viable technology currently available to produce true Type I human collagen. Collagen is an essential building block of the human body, providing structural support and biological signals to connective tissues and organs, and therefore it is a crucial component for tissue regeneration. CollPlant’s proprietary technology includes the introduction into tobacco plants, of 5 human genes that are essential for the synthesis of Type I collagen. The tobacco plant then proceeds to yield human collagen that is superior to the collagen(s) currently in the market, sourced from animals, or even human cadavers. rhCollagen is identical to natural human collagen, therefore it does not elicit an immune response in humans. Its plant origin yields a safe product with more consistent properties, making it the ideal building block/scaffolding molecule for regenerative medicine. CollPlant’s rhCollagen is a broadly applicable technology platform that is cost effective and enables products for medical uses with superior biological and physical properties.

Products

  • BioInks for 3D Bioprinting of Tissues and Organs: Recently, 3D bioprinting has been gaining momentum in many medicinal applications to address the need for complex scaffolds needed for generation of tissues and organs suitable for transplantation. CollPlant’s rhCollagen-based BioInks are ideal for 3D bioprinting due to their safety profile, as well as their biological and physical properties. rhCollagen enables an unlimited, economical supply of organs around the world. Currently, 3D bioprinting is primarily used in R&D, as the technology is moving towards commercialization of manufactured lifesaving organs including lungs, liver, kidney and heart. United Therapeutics (UTHR), a leader in the field, has entered a licensing agreement with CollPlant, valued at up to $44 M plus royalties, for use of CollPlant’s BioInks for the manufacture of lungs. The ability to manufacture organs could save nearly a million lives in the U.S. alone, where 30,000 organ transplants are done each year and 900,000 people die every year due to organ impairment.
  • Advanced Wound Care and Orthobiologics: CollPlant serves the $6.7 B Orthobiologics market with its soft tissue repair product, VergenixSTR. The product is designed for the treatment of tendinopathy, accounting for over 3 million procedures per year in the US alone. Advanced wound care treatment is a $6.2 B market which CollPlant serves through its VergenixFG product, a wound filler for acute and chronic wounds. The size of the target market for Vergenix products is approximately $5 B. Both products were recently launched in Europe and CollPlant is currently working on filing for FDA approval in the U.S.

Contact
Yehiel Tal yehiel@collplant.com

How To Support

ISBF has dedicated a Sponsors’ Section to facilitate more interaction throughout the biofabrication community. As such, we have dedicated a Sponsors’ Section to provide up-to-date information on new tools and products available for research. We hope that your organization will support the mission of ISBF and participate in highlighting your products and technologies here on the ISBF website.
The ISBF offers a special inaugural discount to be a sponsor to ISBF for €1,500 for 1 year. The benefits include the following:
  • One complimentary ISBF membership with all members benefits
  • Your company’s logo displayed on the website’s homepage
  • 1 year of continuous posting on the ISBF website with the description of your company and its products and technologies (1 page) with a direct link to your company’s homepage
  • Acknowledgement of your company’s sponsorship to ISBF on every email communication (eblast) sent out by the society (company’s logo) to the Biofabrication community
  • Complimentary job postings on the ISBF website
To take advantage of this introductory opportunity to support ISBF and highlight your company on the society’s webpage, please click the button below.

Become A Sponsor!

Wake Forest Institute for Regenerative Medicine

Our Mission: To improve patients’ lives by developing regenerative medicine therapies and support technologies.

The Wake Forest Institute for Regenerative Medicine is recognized as an international leader in translating scientific discovery into clinical therapies. Its physicians and scientists were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this team is working to engineer replacement tissues and organs and develop healing cell therapies for more than 40 different areas of the body.

Read More About WFIRM

With the goal of speeding the process of discovery, the institute is designed for collaboration – scientists in the fields of biomedical and chemical engineering, cell and molecular biology, biochemistry, physiology, materials science, nanotechnology, genomics, proteomics, surgery and medicine work side by side. The institute has invested in a Good Manufacturing Practices/Good Tissue Practices facility which operates under guidelines of the U.S. Food and Drug Administration to hasten the delivery of technologies to patients. Several regenerative medicine therapies developed by the institute scientists are already in patients, and others in the pipeline.

Institute research focuses on a wide range of engineered replacement tissues and restorative cell therapies with the aim of making a lasting impact on conditions ranging from diabetes to heart disease. Projects range from engineered heart valves and blood vessels to technology to print skin cells directly on burns. The institute is working to apply the science of regenerative medicine to battlefield injuries through leading a $75-million federally funded project, the Armed Forces Institute for Regenerative Medicine II.

The institute offers a full range of educational and training programs to expose and educate students, teachers, scientists and the public. These programs highlight career opportunities in the biosciences while attracting the next generation of talent in the field of regenerative medicine. Programs include the annual Regenerative Medicine Essentials Course, High School Summer Research Exposure Program, Visiting International Scholars Program, Summer Scholars Program and National Institutes of Health Predoctoral Training Program.

More than 450 scientists collaborate on regenerative medicine research at the institute, the largest in the world. The institute is part of Wake Forest University and is located in the Innovation Quarter in downtown Winston-Salem, NC. Through partnerships and collaborations with many regenerative medicine centers internationally, the institute, which is driven by the urgent needs of patients, is making a global difference in the world of regenerative medicine.

336-713-7293
regenmed@wakehealth.edu

@WFIRMnews
Twitter and Facebook